Several analysts have recently updated their ratings and price targets for BioMarin Pharmaceutical (NASDAQ: BMRN):
- 8/31/2026 – BioMarin Pharmaceutical had its price target raised by Jefferies Financial Group Inc. from $104.00 to $105.00. They now have a “buy” rating on the stock.
- 8/31/2026 – BioMarin Pharmaceutical had its price target raised by HC Wainwright from $59.00 to $60.00. They now have a “neutral” rating on the stock.
- 8/26/2026 – BioMarin Pharmaceutical was given a new $88.00 price target by UBS Group AG.
- 8/19/2026 – BioMarin Pharmaceutical is now covered by BMO Capital Markets. They set an “outperform” rating and a $98.00 price target on the stock.
- 8/18/2026 – BioMarin Pharmaceutical was upgraded by BMO Capital Markets to “strong-buy”.
- 8/18/2026 – BioMarin Pharmaceutical had its price target lowered by HC Wainwright from $60.00 to $59.00. They now have a “neutral” rating on the stock.
- 8/17/2026 – BioMarin Pharmaceutical had its price target raised by Piper Sandler from $82.00 to $88.00. They now have an “overweight” rating on the stock.
- 8/17/2026 – BioMarin Pharmaceutical had its price target raised by Barclays PLC from $105.00 to $111.00. They now have an “overweight” rating on the stock.
- 8/11/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d)”.
- 8/10/2026 – BioMarin Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $111.00 to $114.00. They now have a “buy” rating on the stock.
- 8/8/2026 – BioMarin Pharmaceutical was upgraded by Wall Street Zen from “hold” to “buy”.
- 8/7/2026 – BioMarin Pharmaceutical had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $97.00. They now have an “outperform” rating on the stock.
- 8/7/2026 – BioMarin Pharmaceutical had its price target raised by Morgan Stanley from $119.00 to $124.00. They now have an “overweight” rating on the stock.
- 8/7/2026 – BioMarin Pharmaceutical had its price target raised by HC Wainwright from $50.00 to $60.00. They now have a “neutral” rating on the stock.
- 7/16/2026 – BioMarin Pharmaceutical had its price target raised by Citigroup Inc. from $75.00 to $76.00. They now have a “buy” rating on the stock.
- 7/14/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by UBS Group AG.
- 7/14/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright.
- 7/7/2026 – BioMarin Pharmaceutical had its price target lowered by Royal Bank Of Canada from $66.00 to $62.00. They now have a “sector perform” rating on the stock.
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company’s commercial portfolio includes several approved therapies targeting inherited disorders.
Recommended Stories
- Five stocks we like better than BioMarin Pharmaceutical
- Analysts See Major Upside for This Top-10 Performing S&P 500 Stock
- Cook Out, Silicon In: Will Ternus Trigger Apple’s Edge AI Boom?
- Qualcomm’s AI Ambitions Run Into a Smartphone Reality Check
- Palantir’s Sovereign AI Pitch Tests Microsoft’s Cloud-First AI Bet
Receive News & Ratings for BioMarin Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.
